1350 ET - Moderna shares rise 14% as its patent-infringement settlement was better than investors feared, William Blair analysts say in a note. Investors were contemplating the impact of the legislation being close to $5 billion, which could have raised liquidity concerns, the analysts say. The settlement also creates more certainty for funding late-stage oncology developments in 2026, which look like long-term growth drivers, they say. The analysts maintain their market perform rating but are more constructive on the stock as more clearing events like this one occur. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

March 04, 2026 13:50 ET (18:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.